SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have pleiotropic properties beyond blood glucose–lowering effects and modify important nonglycemic pathways, leading to end-organ protection. SGLT2 inhibitors display renoprotective effects in diabetic kidney disease, which creates a rationale for te...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCI Insight
Autors principals: Cassis, Paola, Locatelli, Monica, Cerullo, Domenico, Corna, Daniela, Buelli, Simona, Zanchi, Cristina, Villa, Sebastian, Morigi, Marina, Remuzzi, Giuseppe, Benigni, Ariela, Zoja, Carlamaria
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6129124/
https://ncbi.nlm.nih.gov/pubmed/30089717
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.98720
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars